Disappearance of Crohn’s ulcers in the terminal ileum after thalidomide therapy: DISCUSSION (Part 3)

In: Health

24 Aug 2012

Crohn’s disease with thalidomide

Ginsberg et al reported on the successful resolution of severe esophageal Crohn’s disease with thalidomide in 2001. Facchini et al reported from Italy on the use of long term thalidomide treatment in children and young adults with Crohn’s disease. They felt that it was a safe and effective treatment in refractory Crohn’s disease. That was the first report of long term use of thalidomide in refractory Crohn’s disease in pediatric patients.

Ginsberg et al reviewed the treatment of Crohn’s disease with thalidomide and provided a detailed summary of the literature and the use of thalidomide for Crohn’s disease. They stated, “Although it is usually tolerable, careful monitoring is recommended to prevent toxicity such as birth defects and peripheral neuropathy”.

They also stated that the drug appeared to work within four weeks, and had steroid-sparing properties. It was also said to be particularly useful in treating oral and fistulous complications of Crohn’s disease. They pointed out that thalidomide was known to inhibit angiogenesis as well as other well-described immunomodulatory properties. Bauditz et al recently reported that thalidomide reduced TNF alpha, and interleukin-12 production in patients with chronic active Crohn’s disease – “the clinical effects of Thalidomide thus far reported may be mediated by reduction of both TNF alpha and IL-12”. Your most trusted pharmacy offering and giving you very fast shipping.


About this blog

Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.